找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Drug Discovery in Japan; Investigating the So Sadao Nagaoka Book 2019 Springer Nature Singapore Pte Ltd. 2019 Drug discovery.breakthrough.u

[复制链接]
楼主: Halcyon
发表于 2025-3-25 03:47:19 | 显示全部楼层
https://doi.org/10.1007/978-94-007-6149-0ncertainty; (D) uniqueness and competition in discovery; and (E) implications on management and policy. We hope that the discussion of these topics will deepen our understandings of pharmaceutical innovations.
发表于 2025-3-25 09:58:51 | 显示全部楼层
发表于 2025-3-25 12:38:24 | 显示全部楼层
Sources of Innovation of Drug Discovery in Japan and Its Implications,ncertainty; (D) uniqueness and competition in discovery; and (E) implications on management and policy. We hope that the discussion of these topics will deepen our understandings of pharmaceutical innovations.
发表于 2025-3-25 16:16:07 | 显示全部楼层
发表于 2025-3-25 20:01:03 | 显示全部楼层
发表于 2025-3-26 00:39:48 | 显示全部楼层
发表于 2025-3-26 05:22:31 | 显示全部楼层
Rosuvastatin (Crestor),otency, together with atorvastatin (Lipitor). Relative to the earlier statins, rosuvastatin was a very late entrant into the market. However, Crestor became a highly successful global blockbuster drug. In the global competition to discover synthetic statins with stronger efficacy than the statins fr
发表于 2025-3-26 11:14:46 | 显示全部楼层
Leuprorelin (Leuplin, Lupron, Viadur), of luteinizing hormone-releasing hormone (LH-RH). Researchers at Takeda Pharmaceutical synthesized the active ingredient using the characterized primary structure of thyrotropin-releasing hormone (TRH) and LH-RH as a model, both discovered within academia. Their research was aided partly by luck an
发表于 2025-3-26 16:41:47 | 显示全部楼层
发表于 2025-3-26 17:37:46 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-4 18:34
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表